Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.

<h4>Background</h4>Tamoxifen is still the most widely used drug in hormone therapy for the treatment of breast cancer. Its benefits in adjuvant treatment are well documented in controlled and randomized clinical studies, which have demonstrated an increase in disease-free intervals of pa...

Full description

Saved in:

Bibliographic Details
Main Authors:	Valentina Folgiero, Paolo Avetrani, Giulia Bon, Selene E Di Carlo, Alessandra Fabi, Cecilia Nisticò, Patrizia Vici, Elisa Melucci, Simonetta Buglioni, Letizia Perracchio, Isabella Sperduti, Laura Rosanò, Ada Sacchi, Marcella Mottolese, Rita Falcioni
Format:	article
Language:	EN
Published:	Public Library of Science (PLoS) 2008
Subjects:	Medicine R Science Q
Online Access:	https://doaj.org/article/66d59f94593e4c78821476da0f2174ef
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.

Similar Items